San Diego, United States
Avenzo Therapeutics is a promising entrant in the Biotechnology sector, primarily focused on advancing oncology therapies. Founded in 2022 and headquartered in the United States, the company is carving its niche in the Health Care and Health and Wellness industries.
The company's mission statement, encapsulated in its slogan—"Developing the next generation of oncology therapies for patients"—underscores its commitment to addressing critical needs in cancer treatment innovation. Such a focus is increasingly vital, considering the global demand for advanced therapeutic solutions.
Recently, Avenzo Therapeutics secured a substantial $60.00M Series B investment as of 01 September 2025. This funding round saw participation from influential investors, including Lilly Asia Ventures, Longwood Fund, OrbiMed, Sofinnova Investments, and NEA, among others. This high-caliber investor interest highlights the market's confidence in the company’s potential to make significant strides in its field. Overall, Avenzo Therapeutics positions itself as a key player to watch in the evolving landscape of oncology therapeutics.
